What about breast cancer?
The main targets for breast cancer treatment are the following:
I. HER2 Target treatment for positive breast cancer
1. Trato Jolly: This was the first targeted drug for HeR2 positive breast cancer to be used in clinical applications. It combines specifically with HeR2 receptors and inhibits the growth and growth of tumour cells. Usually used in combination with chemotherapy, this significantly improves the treatment and survival of HeR2 positive breast cancer patients.
Pato-Choose resistance: Unlike the curto-Choose anti-activation mechanism, Pato-Choose resistance to different areas that combine with HeR2 receptors prevents the formation of HeR2 and other HeR family receptors into an exotic diplex, thus further inhibiting the growth of tumour cells. It is used in conjunction with tratophorus and chemotherapy and is one of the standard treatment programmes for positive breast cancer in Her2.
3.ado-Turtojole is anti-Ntensin (T-DM1): it is made up of a combination of tuttocholes and cytotoxic drugs Ntensin, which have both a curtoric-resistant target and an anti-tumour activity for cytotoxic drugs. For second-line and subsequent treatment of patients with later positive breast cancer in Her2
II. Target treatment for other targets
1. Lapatini: an oral small-molecular carbamate anesthesia inhibitor that simultaneously inhibits Her2 and skin growth factor receptor (EGFR). The main use is for second-line treatment of patients with positive breast cancer in the aftermath of the failure of the one-size-fits-all treatment.
2. Catatini: It is also an oral mercuric carbide accelerant, which has a strong inhibitive effect on Her2. The treatment of positive breast cancer shows better efficacy and safety.
III. PARP Depressants
For breast cancer patients with a BRCA1/2 genetic mutation, PARP inhibitors such as Orapali may have some therapeutic effect. PARP inhibitors induce tumour cells to die by inhibiting DNA damage repair mechanisms.
It should be noted that target-oriented treatment does not apply to all patients with breast cancer and that it is up to the doctor to decide on the use of target-oriented treatment and the choice of appropriate target-oriented drugs, depending on the patient ‘ s specific circumstances, such as the molecular stratification of the tumor, the results of genetic tests, etc. At the same time, there may be adverse effects such as cardiac toxicity, allergies, diarrhoea, etc., that patients should follow their health closely during treatment and provide timely feedback to doctors.
